Most drugs that begin human testing never reach patients, with failure rates high enough that the entire cost structure of the industry is built around the assumption that the large majority of candidates will not work.
The reason trials are so elaborate is that human intuition about whether a treatment works is unreliable in specific, well-documented ways. People improve for reasons unrelated to treatment, doctors see what they expect, and comparing treated patients against untreated ones is misleading unless the two groups were assembled by chance. Nearly every feature of trial design exists to defeat one of these failures.
Why Anecdote Is Not Enough
Many conditions improve on their own, fluctuate naturally, or respond to attention alone, which means a patient who improves after treatment provides little evidence that the treatment worked.
People also tend to seek treatment when symptoms are at their worst, so subsequent improvement toward their usual state is expected regardless of intervention.
This effect is strong enough that convincing patient testimony exists for treatments later shown to be useless or harmful, which is why individual experience cannot settle the question.
What Randomisation Actually Achieves
Assigning patients to treatment or control by chance ensures the two groups differ only randomly, rather than in ways that also affect outcome.
Without it, healthier or more motivated patients tend to receive the newer treatment, which makes it appear effective when the difference reflects who was selected.
Randomisation balances not only known factors like age and severity but unknown ones too, which is what no amount of statistical adjustment can reliably replicate.
Why Allocation Concealment Matters
Randomisation fails if whoever enrols patients can predict the next assignment, since they may consciously or unconsciously steer certain patients toward a particular arm.
Concealment means the upcoming allocation is genuinely unknown at the moment of enrolment, typically handled by a central system rather than by sealed envelopes.
Studies with inadequate concealment consistently report larger treatment effects than those with proper procedures, which suggests the bias is substantial rather than theoretical.
How Blinding Prevents Distortion
If patients know they received the active treatment, their reported symptoms shift, and if clinicians know, their assessment and subsequent care shift as well.
Double blinding conceals allocation from both, which removes expectation as an explanation for any difference observed between groups.
Outcome assessors are also blinded where possible, since judgement is involved in scoring many outcomes and expectation influences it measurably.
What a Placebo Control Is For
A placebo makes blinding possible by ensuring both groups receive something indistinguishable, so participants cannot infer their allocation from what they were given.
It is not there because placebos have healing power, but because comparing treatment against nothing conflates the drug's effect with everything else about receiving care.
Where an effective treatment already exists, using a placebo may be unethical, and the new treatment is compared against standard care instead.
Why the Placebo Effect Is Misunderstood
The placebo group frequently improves, which is widely interpreted as evidence that belief heals, but most of that improvement is natural recovery and measurement artefact.
Studies comparing placebo against no treatment at all find genuine placebo effects are modest and largely confined to subjective outcomes such as pain.
This matters because it means placebo controls are needed to isolate drug effects rather than because placebos themselves are a meaningful therapy.
What Each Trial Phase Establishes
Early human testing involves small numbers, frequently healthy volunteers, and is designed to identify dangerous effects and establish tolerable dosing rather than to show benefit.
The middle stage tests whether the treatment appears to work in patients with the condition, using enough people to detect a plausible effect but not enough to be conclusive.
The final stage is large and randomised, comparing against existing care to establish whether benefit is real and how it compares to what is already available.
Why Most Candidates Fail
The majority of treatments entering human testing do not reach approval, with the largest share failing because they simply do not work well enough despite promising earlier results.
Animal models and laboratory findings translate to humans poorly, which is why apparently strong preclinical evidence is a weak predictor of clinical success.
This attrition is the central economic fact of drug development, since the cost of successes must cover the far larger number of failures.
How Sample Size Is Determined
The number of participants is calculated in advance based on how large an effect would be worth detecting and how confident the result needs to be.
Underpowered trials are a genuine problem, since they frequently produce inconclusive results while exposing participants to risk without generating usable evidence.
Excessively large trials raise a different issue, since they can detect differences too small to matter clinically while being reported as statistically significant.
What Statistical Significance Does Not Mean
A significant result indicates the observed difference would be unlikely if the treatment had no effect, which is not the same as showing the treatment definitely works.
It says nothing about how large the effect is, so a trial can produce a highly significant result describing a benefit too small to be worth having.
This is why effect sizes and confidence intervals are more informative than significance alone, and why reporting standards increasingly require them.
Why Surrogate Endpoints Are Contested
Trials frequently measure something believed to predict a clinical outcome, such as a blood marker, because waiting for actual outcomes takes far longer.
This accelerates development but risks approving treatments that improve the marker without improving how patients actually fare.
Several drugs have been approved on surrogate measures and later found to provide no benefit or to cause harm, which is why the practice remains genuinely debated.
How Pre-Registration Prevents Manipulation
Trials are now required to publish their design and primary outcome measure before enrolment begins, which fixes what will be reported as the main result.
Without this, researchers could measure many outcomes and report whichever appeared favourable, which produces apparently positive findings from data containing nothing.
Comparing registrations against published papers reveals that outcome switching still occurs, which is why registries function as an accountability tool rather than merely a database.
Why Publication Bias Is the Larger Problem
Trials with positive results are considerably more likely to be published than those finding no effect, which distorts the visible evidence base.
This means a treatment can appear effective in the literature while the complete set of trials, including unpublished ones, shows no benefit at all.
Documented cases exist where multiple negative trials remained unpublished for years while the treatment was widely prescribed on the strength of published positive ones.
What Intention to Treat Analysis Prevents
Participants are analysed in the group they were randomised to, even if they stopped taking the treatment or switched, which seems counterintuitive.
The reason is that people who discontinue frequently do so because of side effects or worsening illness, so excluding them removes exactly the patients who fared worst.
Analysing only those who completed treatment reliably exaggerates benefit, which is why the more conservative approach is the standard for regulatory decisions.
How Interim Analysis Works
Long trials are monitored by an independent committee that examines accumulating data while investigators remain blinded, allowing early stopping if warranted.
Trials may stop early for harm, for overwhelming benefit, or for futility when it becomes clear no useful difference will emerge.
Stopping early for benefit tends to overestimate effect size, since trials are more likely to be stopped when random fluctuation happens to favour treatment.
Why Subgroup Analyses Mislead
Examining whether a treatment worked better in particular groups seems reasonable, but testing many subgroups will produce apparently significant findings by chance alone.
A famous demonstration divided trial participants by astrological sign and found statistically significant differences, illustrating how readily such analyses generate nonsense.
Legitimate subgroup analysis must be specified in advance and interpreted cautiously, and findings generated after the fact are treated as hypotheses rather than conclusions.
What Trial Populations Leave Out
Trials frequently exclude older patients, those with multiple conditions, pregnant women, and people taking other medications, which produces cleaner data but limits applicability.
The excluded groups are frequently those most likely to receive the treatment once approved, meaning the evidence applies least well to those who will actually use it.
Regulators have pushed for broader enrolment, though this conflicts with the statistical advantage of studying a uniform population.
Why Diversity in Trials Matters Medically
Drug metabolism varies between populations for genetic reasons, and a dose established in one group may be inappropriate for another.
Historical underrepresentation means some treatments were approved with limited evidence about how they perform in the populations that use them most.
This is a scientific issue rather than only an equity one, since applying findings beyond the studied population is an assumption rather than a demonstrated fact.
How Informed Consent Developed
Modern consent requirements emerged from documented abuses in which people were enrolled in research without knowledge or against their interests.
Participants must be told what is known and unknown, what the risks are, and that they may withdraw at any point without affecting their care.
Genuine understanding rather than a signature is the standard, which is difficult when participants are seriously ill and may conflate research participation with treatment.
Why Ethics Committees Review Everything
Independent committees assess whether the scientific question justifies the risk, whether consent is adequate, and whether vulnerable participants are appropriately protected.
They also assess whether the trial is capable of answering its question, since exposing people to risk in a study too small to be informative is itself unethical.
Approval is required before enrolment and continues through the trial, with serious adverse events reported as they occur rather than only at the end.
What Equipoise Requires
Randomising patients is only ethical when there is genuine uncertainty about which arm is better, a condition described as equipoise.
If evidence accumulates during a trial showing one arm is clearly superior, continuing to randomise becomes unjustifiable and the trial should stop.
This is why monitoring committees exist separately from investigators, since those running a trial have an interest in completing it that may conflict with participant welfare.
How Meta-Analysis Combines Evidence
Individual trials are frequently too small to settle a question, so results from multiple trials are combined statistically to produce a more precise estimate.
This is more reliable than any single trial provided the included studies are sound, but combining flawed trials produces a precise estimate of a biased number.
Meta-analyses also depend on locating all relevant trials, which publication bias makes difficult and which is why registries matter for evidence synthesis.
Why Systematic Reviews Sit Above Trials
A systematic review searches comprehensively for all evidence on a question using a pre-specified method, rather than citing whichever studies support a position.
This addresses the problem that any conclusion can be supported by selecting favourable studies, which ordinary literature reviews permit.
Assessment of study quality is built in, so a review can conclude that the available evidence is too weak to answer the question, which is a legitimate finding.
What Happens After Approval
Trials involve thousands of participants over months, which cannot detect rare adverse effects or those emerging after years of use.
Post-marketing surveillance monitors treatments in the far larger population using them, and several drugs have been withdrawn on the basis of this evidence.
This means approval reflects a judgement that benefits outweigh known risks rather than a conclusion that a treatment is fully characterised.
How Emergency Approval Differs
During public health emergencies, regulators may authorise use before the full evidence package exists, accepting greater uncertainty against the cost of delay.
This compresses timelines by running stages in parallel and by manufacturing before approval, rather than by reducing the number of participants studied.
The trials themselves remain randomised and controlled, which is why rapid development is not the same as lowered evidential standards.
Why Funding Source Affects Results
Trials funded by a treatment's manufacturer report favourable results more often than independently funded trials of the same treatments.
The mechanism is generally not fabrication but design choices, including comparator selection, dosing, outcome measures and which results get published.
This is why funding disclosure is required and why independent replication carries weight beyond the statistical strength of any individual study.
How to Read a Trial Result Sensibly
The useful questions are what the treatment was compared against, how large the absolute benefit was, and whether the outcome measured is one patients would care about.
Relative risk reductions sound impressive while describing small absolute changes, which is why a large percentage improvement may mean very little in practice.
Checking whether the reported primary outcome matches the registered one is a simple test that catches a meaningful proportion of misleading reports.
What the System Actually Delivers
Trial methodology exists because human judgement about treatment effects is unreliable in predictable ways, and each design feature counters a specific known failure.
The result is slow, expensive and frequently frustrating, but it is the reason treatments in routine use are known to work rather than merely believed to.
Its main weakness is not the method but its incomplete application, since selective publication and outcome switching undermine an otherwise sound system.
Why Recruitment Is the Usual Bottleneck
A large proportion of trials fail to enrol their target number of participants, and many close early having answered nothing.
Patients are frequently unaware trials exist, clinicians lack time to discuss them, and eligibility criteria exclude most of the people who might benefit.
This wastes both the resources spent and the risk borne by those who did participate, which makes recruitment a scientific problem rather than only an administrative one.
What Crossover Designs Allow
In some trials each participant receives both the treatment and the control in sequence, which means they serve as their own comparison.
This substantially reduces the number of people needed, since differences between individuals are removed from the comparison entirely.
It only works for stable conditions where the treatment does not cure or permanently alter the patient, which limits it to a narrow set of questions.
Why Non-Inferiority Trials Exist
Sometimes the aim is not to show a treatment is better but that it is not meaningfully worse, while offering another advantage such as fewer side effects.
These trials define in advance how much worse would still be acceptable, which is a judgement rather than a statistical fact and is frequently contested.
The design is more vulnerable to sloppiness, since anything that blurs the difference between arms pushes the result toward the desired conclusion.
How Adaptive Trials Change the Rules
Adaptive designs allow pre-specified modifications during the trial, including dropping ineffective arms or shifting allocation toward better-performing ones.
This can answer questions faster and expose fewer participants to treatments that are not working, which is both efficient and ethically attractive.
The adaptations must be planned in advance and accounted for statistically, since changing a trial in response to results without doing so invalidates the analysis.
Clinical trial design is not bureaucratic excess. Every feature counters a specific, documented way human judgement goes wrong. People improve on their own and seek treatment when symptoms peak, so anecdote proves nothing. Doctors and patients both report what they expect, so blinding is required. Healthier patients gravitate toward newer treatments, so allocation must be random and genuinely concealed β trials with weak concealment consistently report bigger effects than those with proper procedures. Several standard practices look wrong until the reason is clear. Analysing people in the group they were assigned to, even after they stopped taking the drug, seems perverse β but those who discontinue usually do so because of side effects or worsening illness, so excluding them deletes exactly the patients who fared worst. Similarly, stopping a trial early because results look good tends to overstate the effect, since random fluctuation is what triggered the stop. The biggest weakness is not the methodology but its incomplete application. Positive trials get published far more often than negative ones, so a treatment can look effective in the literature while the full set of trials shows nothing. Registries and pre-specified outcomes exist to catch this, and comparing what was registered against what was published remains one of the most useful checks available.
Sources
- Wikipedia β trial phases, design and regulatory context
- Cochrane β systematic review methodology and evidence synthesis
- World Health Organization β international trial registry and reporting standards
- US Food and Drug Administration β approval requirements and post-marketing surveillance
- BMJ β research on publication bias, outcome switching and funding effects
FAQ
Why do trials need a placebo group?
To make blinding possible and to separate the drug's effect from natural recovery and from everything else about receiving care. Not because placebos themselves are a meaningful therapy.
Why analyse people who stopped taking the drug?
Because those who discontinue usually do so due to side effects or worsening illness. Excluding them removes the patients who fared worst and exaggerates the benefit.
Does statistical significance mean a treatment works?
Not quite. It means the difference would be unlikely if there were no effect. It says nothing about how large that effect is or whether it matters clinically.
Why do most drugs fail?
Most simply do not work well enough in humans despite promising laboratory and animal results, which translate to people poorly. This attrition drives the economics of drug development.
Was emergency vaccine approval less rigorous?
Timelines were compressed by running stages in parallel and manufacturing before approval, not by shrinking trials. The trials remained randomised and controlled.
About the Author
We reference Wikipedia, Cochrane, World Health Organization, US Food and Drug Administration, and BMJ to explain the background and current understanding of this topic.
Loved This Article?
Share it on WhatsApp β Share it on WhatsApp
Get more guides in your inbox β Subscribe to our newsletter for weekly surprising stories from Egypt, Saudi Arabia, Dubai, and beyond.